Key Takeaways
- Eli Lilly's (LLY) oral GLP-1 drug, Orforglipron, demonstrated superior efficacy over oral semaglutide in the ACHIEVE-3 trial, achieving a 2.2% A1C reduction and 19.7 pounds of weight loss at its highest dose, with a safety profile consistent with previous trials.
- Goldman Sachs (GS) has further boosted its China 2025 GDP growth forecast to 4.8%, reflecting continued optimism for the nation's economic momentum.
- Kraken and Circle (CRCL) have announced a strategic partnership aimed at accelerating the global access and utility of USDC and EURC stablecoins.
- The U.S. Federal Reserve's effective federal funds rate remained steady at 4.33% on September 16, as market participants eagerly await today's press conference with FOMC Chair Jerome Powell.
The financial world is abuzz with a flurry of significant developments, ranging from groundbreaking pharmaceutical trial results to revised economic forecasts and crucial central bank communications. Eli Lilly's (LLY) oral GLP-1 agonist, Orforglipron, has shown impressive efficacy in its latest Phase 3 trial, while Goldman Sachs (GS) has once again raised its outlook for China's 2025 GDP growth. In the cryptocurrency space, a major partnership between Kraken and Circle (CRCL) aims to expand stablecoin utility. All eyes are also on Washington D.C. as Federal Reserve Chair Jerome Powell prepares for a highly anticipated press conference following the latest interest rate data.
Eli Lilly's Orforglipron Shows Strong Performance in ACHIEVE-3 Trial
Eli Lilly and Company (LLY) has reported positive topline results from its ACHIEVE-3 Phase 3 clinical trial, evaluating the safety and efficacy of its investigational oral GLP-1 receptor agonist, Orforglipron, against oral semaglutide in adults with type 2 diabetes. The overall safety and tolerability profile of Orforglipron in ACHIEVE-3 was consistent with past trials.
In a head-to-head comparison, Orforglipron demonstrated superior glycemic control and weight loss. Participants receiving the highest dose of Orforglipron experienced an average A1C reduction of 2.2%, significantly outperforming the 1.4% reduction seen with the highest dose of oral semaglutide. Furthermore, patients on the highest dose of Orforglipron achieved an average weight loss of approximately 19.7 pounds, compared to 11 pounds for those on oral semaglutide, representing a 73.6% greater relative weight loss. These results position Orforglipron as a potentially powerful new oral treatment option for type 2 diabetes and associated weight management.
Goldman Sachs Raises China's 2025 GDP Growth Forecast
Goldman Sachs (GS) has once again revised its forecast for China's gross domestic product (GDP) growth in 2025, now projecting an increase to 4.8%. This latest revision follows earlier upgrades, with the investment bank having previously raised its 2025 forecast to 4.7% from 4.3% in October 2024, and to 4.6% from 4.0% in May 2025. The upward adjustments reflect growing confidence in China's economic resilience and the efficacy of its pro-growth policies.
Kraken and Circle Forge Stablecoin Partnership
Cryptocurrency exchange Kraken and global financial technology company Circle Internet Group, Inc. (CRCL), a leading stablecoin issuer, have announced a strategic partnership. This collaboration aims to accelerate the global access and utility of USDC and EURC stablecoins.
The partnership is expected to provide Kraken clients with increased liquidity, reduced conversion fees, and new opportunities to deploy USDC across Kraken's applications. Additionally, Kraken will introduce access to EURC, Circle's fully reserved euro stablecoin, further expanding the stablecoin offerings available on the platform. This move underscores the continued expansion and integration of stablecoins into mainstream financial applications.
Federal Reserve Holds Rate Steady, Powell's Press Conference Awaited
The U.S. Federal Reserve's effective federal funds rate remained unchanged at 4.33% on September 16, with daily trades totaling $98 billion, an increase from $91 billion on September 15. This stability precedes a highly anticipated event today: a press conference with Federal Open Market Committee (FOMC) Chair Jerome Powell at 2:30 p.m. ET.
Markets are closely watching for signals regarding the central bank's future monetary policy, particularly after a period of rate cuts in the latter half of 2024. Analysts expect Powell to provide insights into the FOMC's economic outlook and potential future rate adjustments, which could significantly influence investor sentiment and market direction.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.